130 related articles for article (PubMed ID: 24648895)
1. Improvement of metabolic syndrome by irbesartan via the PPARγ/HGF pathway in apolipoprotein E knockout mice.
Chatterjee A; Kusunoki H; Taniyama Y; Rakugi H; Morishita R
Biomed Rep; 2013 Jan; 1(1):65-70. PubMed ID: 24648895
[TBL] [Abstract][Full Text] [Related]
2. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
Kusunoki H; Taniyama Y; Rakugi H; Morishita R
J Am Heart Assoc; 2013 Apr; 2(2):e000103. PubMed ID: 23608606
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory effects of hepatocyte growth factor on the vicious cycle of macrophages and adipocytes.
Kusunoki H; Taniyama Y; Otsu R; Rakugi H; Morishita R
Hypertens Res; 2014 Jun; 37(6):500-6. PubMed ID: 24621470
[TBL] [Abstract][Full Text] [Related]
4. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
6. Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice.
Zhang ZZ; Shang QH; Jin HY; Song B; Oudit GY; Lu L; Zhou T; Xu YL; Gao PJ; Zhu DL; Penninger JM; Zhong JC
J Transl Med; 2013 Sep; 11():229. PubMed ID: 24067190
[TBL] [Abstract][Full Text] [Related]
7. Impact of peroxisome proliferator-activated receptor γ on angiotensin II type 1 receptor-mediated insulin sensitivity, vascular inflammation and atherogenesis in hypercholesterolemic mice.
Tiyerili V; Becher UM; Camara B; Yildirimtürk C; Aksoy A; Kebschull M; Werner N; Nickenig G; Müller C
Arch Med Sci; 2015 Aug; 11(4):877-85. PubMed ID: 26322101
[TBL] [Abstract][Full Text] [Related]
8. The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance.
de las Heras N; Martín-Fernández B; Miana M; Ballesteros S; Oubiña MP; López-Farré AJ; Cachofeiro V; Lahera V
J Hypertens Suppl; 2009 Aug; 27(6):S37-41. PubMed ID: 19633450
[TBL] [Abstract][Full Text] [Related]
9. Irbesartan increased PPARγ activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction.
Iwai M; Kanno H; Senba I; Nakaoka H; Moritani T; Horiuchi M
Biochem Biophys Res Commun; 2011 Mar; 406(1):123-6. PubMed ID: 21296052
[TBL] [Abstract][Full Text] [Related]
10. Differential response of vascular hepatocyte growth factor concentration and lipid accumulation between telmisartan and losartan in ApoE-deficient mice.
Nakagami H; Osako MK; Takami Y; Hanayama R; Koriyama H; Mori M; Hayashi H; Shimizu H; Morishita R
Mol Med Rep; 2008; 1(5):657-61. PubMed ID: 21479465
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
Janke J; Schupp M; Engeli S; Gorzelniak K; Boschmann M; Sauma L; Nystrom FH; Jordan J; Luft FC; Sharma AM
J Hypertens; 2006 Sep; 24(9):1809-16. PubMed ID: 16915030
[TBL] [Abstract][Full Text] [Related]
13. A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice.
Shiomi Y; Yamauchi T; Iwabu M; Okada-Iwabu M; Nakayama R; Orikawa Y; Yoshioka Y; Tanaka K; Ueki K; Kadowaki T
J Biol Chem; 2015 Jun; 290(23):14567-81. PubMed ID: 25907553
[TBL] [Abstract][Full Text] [Related]
14. 15-Deoxy-Delta12,14-prostaglandin J2 inhibits angiotensin II-induced fibronectin expression via hepatocyte growth factor induction in human peritoneal mesothelial cells.
Yokoyama Y; Masaki T; Kiribayashi K; Nakashima A; Kokoroishi K; Ogawa T; Kohno N; Yorioka N
Ther Apher Dial; 2010 Feb; 14(1):43-51. PubMed ID: 20438519
[TBL] [Abstract][Full Text] [Related]
15. Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.
Takai S; Jin D; Miyazaki M
J Pharmacol Sci; 2011; 116(3):309-15. PubMed ID: 21691037
[TBL] [Abstract][Full Text] [Related]
16. Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia.
Rong X; Li Y; Ebihara K; Zhao M; Kusakabe T; Tomita T; Murray M; Nakao K
Br J Pharmacol; 2010 Aug; 160(7):1796-807. PubMed ID: 20649581
[TBL] [Abstract][Full Text] [Related]
17. Suppressive effects of irbesartan on inflammation and apoptosis in atherosclerotic plaques of apoE-/- mice: molecular imaging with 14C-FDG and 99mTc-annexin A5.
Zhao Y; Watanabe A; Zhao S; Kobayashi T; Fukao K; Tanaka Y; Nakano T; Yoshida T; Takemoto H; Tamaki N; Kuge Y
PLoS One; 2014; 9(2):e89338. PubMed ID: 24586699
[TBL] [Abstract][Full Text] [Related]
18. Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.
Dong Y; Xu Z; Zhang Z; Yin X; Lin X; Li H; Zheng F
J Mol Endocrinol; 2017 Apr; 58(3):141-154. PubMed ID: 28258092
[TBL] [Abstract][Full Text] [Related]
19. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
[TBL] [Abstract][Full Text] [Related]
20. Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ.
Nakagami H; Morishita R
Curr Vasc Pharmacol; 2011 Mar; 9(2):162-6. PubMed ID: 21143167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
